Add to Calendar 1/24/2019 8:00:00 AM 1/24/2019 10:00:00 AM Building an IP Fence Around Your Drug Device Combination Product For combination products, device IP can supplement IP covering the drug molecule to add significant further protection. As combination products evolve to operate in a more patient-centered ecosystem, blending drugs, devices, and services to improve patient outcomes, device IP not only encompasses traditional delivery, diagnostic, & monitoring devices, but is also evolving to include hardware, software, and data mining. But complexity, development, and ownership issues make it challenging to secure strategic patent protection to cover this broad range of technologies. This panel will discuss how device IP may add value to your combination product, and how to build such a portfolio. MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139
CEO, Cocoon Biotech Inc.
Dr. Ailis Tweed-Kent is an up-and-coming entrepreneur and leader in the development of innovative medical technologies. With her education in medicine at Harvard Medical School (HMS) and residency in internal medicine at Massachusetts General Hospital (MGH), Ailis has first hand knowledge of the burden of disease. In 2013, Ailis was inspired by her patients to found Cocoon to develop innovative silk therapeutics leveraging silk as a materials science platform. Prior to Cocoon, she worked on the design, development, and delivery of diagnostic technologies for global health collaborating with organizations such as PEPFAR/Office of U.S. Global AIDS Coordinator, London School of Hygiene & Tropical Medicine, and the Global Health Delivery Project. She brings a multidisciplinary approach with a B.S. in Chemical Engineering from the University of Notre Dame. She was recently named to the Boston Business Journal’s 2017 Women to Watch in Science and Technology as well as the Boston MedTech’s 40 Under 40 Healthcare Innovators.